Live Breaking News & Updates on Viatris Biosimilars

Stay updated with breaking news from Viatris biosimilars. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

biocon q3 earnings: Biocon Q3 Results: PAT at Rs 660 crore vs Rs 42-crore loss a year ago

The company said the revenue growth was supported by income from the divesture of two non-core business assets of Biocon Biologics branded formulations India business amounting to Rs 350 crore and a gain of Rs 456 crore from Biocons stake dilution in Bicara Therapeutics. ....

Biocon Biologics , Kiran Mazumdar Shaw , Viatris Biosimilars , Mazumdar Shaw , Biocon Biologic , Emerging Markets , Biocon Q3 Earnings , Biocon Q3 , Biocon Q3 Update , Biocon Q3fy24 Earnings , Biocon Share Price ,

Biocon Biologics to Acquire Viatris' Biosimilars Assets for Up to USD 3.335 Billion in Stock and Cash

She said the deal will enable BBL to attain a robust commercial engine in the developed markets of U.S. & Europe and will fast-track the company s journey of building a strong global brand. Biocon Biologics to Acquire Viatris Biosimilars Assets for Up to USD 3.335 Billion in Stock and Cash. ....

Kiran Mazumdar Shaw , Bharti Airtel , Viatri Biosimilars , Biocon Biologics , Serum Institute Life Sciences , Biocon Biologics Ltd , Biocon Ltd , Compulsorily Convertible Preference Shares , Indus Towers , Executive Chairperson , Viatris Biosimilars ,